Linezolid for multidrug-resistant tuberculosis

摘要

In their Comment in The Lancet Infectious Diseases, Kwok-Chiu Chang and colleagues1 concluded that expansion of access to linezolid for complicated cases of drug-resistant tuberculosis risks the loss of a potentially useful drug and could promote the emergence and spread of drug-resistant tuberculosis in the community. The rationale behind this idea seems to be the scarcity of controlled clinical trials and, in particular, data for optimum linezolid dose.